Latest Content
Sponsor content
Inhibition of CD300f function on dendritic cells promotes tumor destruction: Licensing and Research Collaboration Opportunity
NIAID researchers have discovered that blocking CD300f function in dendritic cells markedly enhances their ability to phagocytose and process apoptotic tumor cells, leading to substantial inhibition of tumor growth. Inhibiting CD300f function on dendritic cells could be a promising anti-cancer therapy, especially in the settings where blocking of T cell checkpoint receptors has been ineffective.
Sponsor content
Prefusion HPIV F Immunogens and Their Use: Licensing Opportunity
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases created immunogenic PIV fusion (F) glycoproteins for types 1,2,3 and 4 (hPIV1, hPIV2, hPIV3 and hPIV4) that have been modified to stabilize the prefusion conformation. These stabilized prefusion F immunogens, especially hPIV3, induced high titer neutralizing responses in mice and rhesus macaques, and should thus serve as promising candidates for the prevention of PIV infection in humans.
Using BioPharma Dealmakers
All about how to get the most from the BioPharma Dealmakers website, whether you are a sponsoring Company or a Member.
Editorial content
Follow us on Twitter
BioPharma Dealmakers has just joined Twitter. Follow us for details of our latest content and partnering news stories.
Medtech dealmaking and financing trends in 2017
Diagnostics dealmaking in the past year
Medtech dealmaking and financing trends in 2016
CNS
The latest from BioPharma Dealmakers on companies, research and deals in the CNS field.
Drug Development
The latest from BioPharma Dealmakers on companies, research and deals in the drug development field.
Academic/Non-profit organisation
The latest from BioPharma Dealmakers on establishments, research and deals from academic and non-profit organisations.
Opening up academic partnerships
Oncology
The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.
Gastrointestinal
The latest from BioPharma Dealmakers on companies, research and deals in the gastrointestinal field.
Dealmaking for inflammatory disorders
Dermatology
The latest from BioPharma Dealmakers on companies, research and deals in the dermatology field.
